Score another legal victory for Fonar. On March 21, the Melville, NY-based company announced that the $2.3 million judgment rendered against Fonar for independent service provider Magnetic Resonance Plus has been set aside. In its decision, the U.S.
Score another legal victory for Fonar. On March 21, the Melville, NY-based company announced that the $2.3 million judgment rendered against Fonar for independent service provider Magnetic Resonance Plus has been set aside. In its decision, the U.S. District Court for the southern district of New York also ordered a new trial, according to Fonar.
In December, a federal jury had awarded MR Plus $2.3 million, but the verdict was later overturned by the appeals court in January, which also reinstated Fonar's copyright-infringement and unfair-competition claims (SCAN 3/5/97).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.